IP Library Granted Patent US 8,030,000
Granted Patent B2
US 8,030,000 · App. 12/660,117 · Granted Oct 4, 2011

Recombinase polymerase amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,030,000
App. No.
12/660,117
Granted
Oct 4, 2011
Kind
B2
Abstract

This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods. Further RPA reactions using light and otherwise, methods to determine the nature of amplified species without a need for gel electrophoresis, methods to improve and optimize signal to noise ratios in RPA reactions, methods to optimize oligonucleotide primer function, methods to control carry-over contamination, and methods to employ sequence-specific third ‘specificity’ probes. Further described are novel properties and approaches for use of probes monitored by light in dynamic recombination environments.

Claims (43)

1. An RPA process of DNA amplification of a double stranded target sequence, said target sequence comprising a first and a second strand of DNA, said process comprising the steps of:

(a) contacting a recombinase agent with a first and a second nucleic acid primer to form a first and a second nucleoprotein primer;

(b) contacting the first and second nucleoprotein primers to said double stranded target sequence thereby forming a first double stranded structure at a first portion of said first strand and form a double stranded structure at a second portion of said second strand such that the 3′ ends of said first nucleic acid primer and said second nucleic acid primer are oriented toward each other on the same template nucleic acid molecule;

(c) extending the 3′ end of said first and second nucleoprotein primer with one or more polymerases and dNTPs to generate a first and second double stranded nucleic acid and a first and second displaced strand of nucleic acid;

(d) continuing the reaction through repetition of (b) and (c) until a desired degree of amplification is reached wherein the generated double stranded nucleic acid can serve as the double stranded target sequence

wherein the RPA process is performed in the presence of at least one recombinase loading protein and at least one single stranded DNA binding protein, wherein said recombinase agent is a uvsX recombinase, said one or more polymerases comprises a DNA polymerase I with strand-displacing properties and which lacks 5′ to 3′ exonuclease activity, said at least one single stranded DNA binding protein is a gp32 single stranded DNA binding protein, and said at least one recombinase loading protein is a uvsY recombinase loading protein; and

wherein the RPA process is performed in the presence of a crowding agent.

2. The process of claim 1 wherein said first or second nucleic acid primers have a length that is below the length required for optimal strand exchange to decrease nonspecific amplification reactions.

3. The process of claim 1 further comprising the step of ligating additional nucleic acid sequence to at least one end of said target nucleic acid before step (b) to reduce foldback priming or to modulate nucleoprotein recombination/elongation rate.

4. The process of claim 1 further comprising the step of monitoring total DNA concentration with a sensor during said process.

5. The process of claim 1 wherein said RPA process is started or controlled by a light-driven photodeprotection of one or more caged substance.

6. The process of claim 5 wherein said caged substance is caged ATP or caged oligonucleotides.

7. The process of claim 5 wherein the concentration of uncaged molecules are monitored.

8. The process of claim 1 wherein one or both of said primers comprise cytosine at greater than 75% of the bases of the primer.

9. The process of claim 1 which is performed in a gel matrix which restricts the mobility of the template nucleic acid and an RPA product.

10. The process of claim 9 wherein said gel matrix is a polony gel matrix.

11. A process of nested RPA comprising the steps of:

(a) performing an RPA reaction of claim 1 in the presence of a first pair of outer primers and a second pair of inner primers in said step (a);

wherein said first pair of outer primers comprise nucleic acid sequence such that the 3′ ends of said pair of outer primers are oriented toward each other on the same template nucleic acid molecule after step (b);

wherein said second pair of inner primers comprise nucleic acid sequence such that the 3′ ends of said pair of inner primers are oriented toward each other on the same template nucleic acid molecule after step (b),

further wherein said second pair of inner primers hybridize to the target nucleic acid at a location that is within the hybridization location of said first pair of outer primers.

12. The process of claim 11 wherein said process is performed in the presence of dUTP such that dUTP is incorporated into an RPA product wherein said RPA product is susceptible to a dUTP deglycosylase.

13. The process of claim 11 wherein said process is performed in the presence of an enzyme selected from the group consisting of DNA ligase, helicase, RNA polymerase, reverse transcriptase, FLAP endonuclease, 5′-3′ exonuclease, 3′-5′ exonuclease, restriction endonuclease, endonuclease and base-specific damaged base-specific nuclease.

14. The process of claim 11 wherein at least one said primer comprise additional nucleic acid sequences which permit optimal seeding and phasing properties of recombinase on the primer.

15. The process of claim 14 wherein the additional DNA sequences comprises more than 70% pyrimidines or more than 75% of cytosine residues.

16. An RPA process of DNA amplification of a double stranded target sequence, said target sequence comprising a first and a second strand of DNA, said process comprising the steps of:

(a) contacting a recombinase agent with a first and a second nucleic acid primer to form a first and a second nucleoprotein primer;

(b) contacting the first and second nucleoprotein primers to said double stranded target sequence thereby forming a first double stranded structure at a first portion of said first strand and form a double stranded structure at a second portion of said second strand such that the 3′ ends of said first nucleic acid primer and said second nucleic acid primer are oriented toward each other on the same template nucleic acid molecule;

(c) extending the 3′ end of said first and second nucleoprotein primer with one or more polymerases and dNTPs to generate a first and second double stranded nucleic acid and a first and second displaced strand of nucleic acid;

(d) continuing the reaction through repetition of (b) and (c) until a desired degree of amplification is reached wherein the generated double stranded nucleic acid can serve as the double stranded target sequence;

wherein the RPA process is performed in the presence of at least one recombinase loading protein and at least one single stranded DNA binding protein, wherein said recombinase agent is a uvsX recombinase, said one or more polymerases comprises a DNA polymerase I with strand-displacing properties and which lacks 5′ to 3′ exonuclease activity, said at least one single stranded DNA binding protein is a gp32 single stranded DNA binding protein, and said at least one recombinase loading protein is a uvsY recombinase loading protein;

wherein one or more of the primers is initially 3′-blocked, and contains a tetrahydrofuranyl residue, and wherein an E. coli Nfo protein is present in said RPA process, wherein a blocked oligonucleotide forms duplex hybrids with a target DNA and is subsequently cleaved by the Nfo protein; and wherein the polymerase extends a free 3′ end of a probe generated by Nfo cleavage.

17. The process of claim 16 , wherein said blocked primer contains a tetrahydrofuranyl residue, a fluorophore, and a quenching minor groove binding dye, such that on forming duplex hybrids the quenching is decreased by virtue of a change in absorption properties of the minor groove binding dye such that a rise in fluorescence emission from the fluorophore increases as a consequence of DNA amplification.

18. The process of claim 16 , wherein step (a) is performed in the presence of a first pair of outer primers and a second pair of inner primers;

wherein said first pair of outer primers comprise nucleic acid sequence such that the 3′ ends of said pair of outer primers are oriented toward each other on the same template nucleic acid molecule after step (b);

wherein said second pair of inner primers comprise nucleic acid sequence such that the 3′ ends of said pair of inner primers are oriented toward each other on the same template nucleic acid molecule after step (b); and

further wherein said second pair of inner primers hybridize to the target nucleic acid at a location that is within the hybridization location of said first pair of outer primers

and wherein one or more of the outer or inner primers is initially 3′-blocked, and contains a tetrahydrofuranyl residue, and wherein an E. coli Nfo protein is present in said RPA process, wherein a blocked oligonucleotide forms duplex hybrids with a target DNA and is subsequently cleaved by the Nfo protein; and wherein the polymerase extends a free 3′ end of a probe generated by Nfo cleavage.

19. The process of claim 18 , wherein said blocked primer contains a tetrahydrofuranyl residue, a fluorophore, and a quenching minor groove binding dye, such that on forming duplex hybrids the quenching is decreased by virtue of a change in absorption properties of the minor groove binding dye such that a rise in fluorescence emission from the fluorophore increases as a consequence of DNA amplification.

20. The process of claim 1 , wherein the crowding agent is selected from the group consisting of polyethylene glycols, dextran, ficoll, and combinations thereof.

21. The process of claim 20 , wherein the crowding agent comprises polyethylene glycol.

22. The process of claim 1 , wherein the crowding agent is present at a concentration of between 1 and 12% by weight or by volume.

23. The process of claim 22 , wherein the crowding agent comprises polyethylene glycol.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
CHANGE OF NAME Recorded Sep 30, 2010
From: ASM SCIENTIFIC, INC.
To: TWISTDX, INC.
Reel/Frame 025066/0515 →
CERTIFICATE OF MERGER Recorded Sep 30, 2010
From: TWISTDX, INC.
To: BIOSITE INCORPORATED
Reel/Frame 025066/0614 →
CHANGE OF NAME Recorded Sep 30, 2010
From: BIOSITE INCORPORATED
To: ALERE SAN DIEGO, INC.
Reel/Frame 025066/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2010
From: PIEPENBURG, OLAF; WILLIAMS, COLIN H.; ARMES, NIALL A.; STEMPLE, DEREK L.
To: ASM SCIENTIFIC, INC.
Reel/Frame 025063/0553 →